DAX24.856 -0,5%Est506.036 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,7200 -0,6%Nas23.066 -0,2%Bitcoin56.806 +0,7%Euro1,1877 ±-0,0%Öl69,60 ±-0,0%Gold5.055 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Gerresheimer A0LD6E SAP 716460 Rheinmetall 703000 BASF BASF11 NVIDIA 918422 Deutsche Telekom 555750 Lufthansa 823212 Commerzbank CBK100 Microsoft 870747 Amazon 906866 Allianz 840400 DroneShield A2DMAA Bayer BAY001 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel in Rot -- US-Börsen kaum bewegt -- Deutsche Börse mit Rekordergebnis -- Siemens Energy: Rekordaufträge -- Lufthansa, Commerzbank, BMW, Telekom, Lyft, Moderna, Robinhood im Fokus
Top News
Ausblick: CANCOM SE legt Zahlen zum jüngsten Quartal vor Ausblick: CANCOM SE legt Zahlen zum jüngsten Quartal vor
Ausblick: Mercedes-Benz veröffentlicht Zahlen zum vergangenen Quartal Ausblick: Mercedes-Benz veröffentlicht Zahlen zum vergangenen Quartal
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

Biogen Aktie

Kaufen
Verkaufen
Biogen Aktien-Sparplan
160,90 EUR +2,10 EUR +1,32 %
BMN
191,14 USD +2,18 USD +1,15 %
BTT
Biogen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.23,35 Mrd. EUR

KGV20,02Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN789617

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS09062X1037

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBIIB

Biogen Aktien News

DatumMeistgelesen
GlobeNewswireBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
PR NewswireLeqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
PR NewswireAlcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
GlobeNewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz
PR NewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The...
GlobeNewswireBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
GlobeNewswireUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
PR NewswireBiogen Inc. Sued for Securities Law Violations - Contact the Schall Law Firm to Discuss Your Legal Rights BIIB
PR NewswireBiogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
PR NewswireBiogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB
PR NewswireShareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
GlobeNewswireBiogen Completes Acquisition of Human Immunology Biosciences
GlobeNewswire“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
PR NewswireBIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
GlobeNewswireTOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB
GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
PR NewswireFDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
PR NewswireFINAL DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
GlobeNewswireBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
PR NewswireBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
GlobeNewswireBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
GlobeNewswireBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
PR NewswireIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
GlobeNewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track St
PR NewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Trac...
GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
PR NewswireEisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
GlobeNewswireNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
GlobeNewswireBiogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
GlobeNewswireBiogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
GlobeNewswireBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GlobeNewswireBiogen to Realign Resources for Alzheimer's Disease Franchise
GlobeNewswireCentralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
GlobeNewswireCHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.